[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontitis-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontitis-adult":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,64,90,118,159,188,213,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644263","evaluation-of-masticatory-performance-in-patients-with-periodontitis-100644263",false,"NCT07665489","Evaluation of Masticatory Performance in Patients With Periodontitis","PAROCHEW","Inclusion Criteria:\n\n* Patients followed at the university hospital (CHU) with a diagnosis of periodontitis.\n* No objection from the patient to participate in the study.\n* Patients able to speak and understand French.\n\nExclusion Criteria:\n\n* Minors.\n* Patients under legal protection (guardianship, trusteeship, or judicial protection measures).\n* Pregnant or breastfeeding women.\n* Patients who refuse to participate in the study.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The objective of this observational study is to assess the correlation between the severity of periodontal involvement and masticatory performance in patients with periodontitis.\n\nThe secondary objectives are to identify periodontal parameters that may be associated with a reduction in masticatory performance.\n\nThis study includes a single group.\n\nParticipants will be asked to perform a masticatory performance test consisting of chewing a piece of gum for 20 cycles.",[24,25,26],"Periodontitis, Adult","Periodontitis","Oral Disease","NOT_YET_RECRUITING","2026-06-30",{"date":30,"type":31},"2026-07-01","ACTUAL",{"date":33,"type":20},"2026-06-01",{"date":35,"type":20},"2027-06-01",{"name":37,"class":38},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100527578","changes-in-microbial-status-from-dentate-edentulous-and-after-dental-implant-placement-100527578","NCT06149585","Changes in Microbial Status From Dentate, Edentulous and After Dental Implant Placement","Inclusion Criteria:\n\n1. At least 21 years of age\n2. Diagnosis of Stage III or IV periodontitis based on full mouth probing and full mouth x-rays\n3. Planned for full mouth extraction and replacement by dental implants.\n4. Rehabilitation with Implant supported restorations either maxilla and\u002F or mandible.\n5. At least 2 implants available for examination.\n6. No bone augmentation required.\n\nExclusion Criteria:\n\n1. Conditions requiring chronic routine prophylactic use of antibiotics.\n2. Conditions requiring prolonged use of steroids.\n3. History of leukocyte dysfunction and deficiencies\n4. Bleeding disorders\n5. History of neoplastic disease requiring use of radiation or chemotherapy\n6. Metabolic bone disorders\n7. Uncontrolled endocrine disorder\n8. Use of any investigational drug or device within the 30 day period prior to implant surgery.\n\n10\\. Alcoholism or drug abuse 11. Patient infected with HIV 12. Condition or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, unreliability.\n\nLocal Exclusion Criteria\n\n1. Local inflammation\n2. Mucosal disease such as erosive lichen planus\n3. History of local irradiation therapy\n4. Osseous lesion.\n5. Active infection with suppuration or fistula track.\n6. Persistent intraoral infection different than periodontitis",true,"21 Years",{"count":49,"type":20},12,"The objectives of this study are to analyze the oral microbiome modulations occurring during the transition from partial (with some residual teeth) to full edentulous (without remaining teeth) status and implant placement in subjects affected by severe periodontitis; to evaluate if microbiome changes in relation to the used of different implant material\u002Fsurface; and to assess the variance of the changes to determine the sample size for future longitudinal prospective studies.",[52,53,24,54],"Edentulous Mouth","Periodontal Diseases","Microbial Colonization","RECRUITING","2026-06-29",{"date":30,"type":31},{"date":59,"type":31},"2023-08-16",{"date":61,"type":20},"2028-05-01",{"name":63,"class":38},"Case Western Reserve University",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100639708","profiling-gingival-crevicular-fluid--catenin-level-with-8-ohdg-and-total-antioxidants-capacity-during-healing-of-periodontal-pockets-a-3-month-clinical-trial-100639708","NCT07596667","Profiling Gingival Crevicular Fluid β-Catenin Level With 8-OHdG and Total Antioxidants Capacity During Healing of Periodontal Pockets: A 3-month Clinical Trial","Inclusion criteria:\n\n* patients over 18 years old\n* patients with periodontal pockets depth more than 4 mm\n\nExclusion criteria:\n\n* Pregnant women\n* patients taking antibiotic within the last three months\n* Patients with systemic disease ( Diabetes mellitus)","60 Years",{"count":72,"type":20},21,"INTERVENTIONAL",[75],"NA","Background: To profile gingival crevicular fluid (GCF) β-Catenin, 8-OHdG, and total antioxidants capacity (TAC) in periodontitis patients during healing of periodontal pockets following non-surgical periodontal therapy (NSPT).Methods: Periodontitis patients (n = 21) will included in this clinical trial. Clinical periodontal parameters will recorded and GCF samples will collected from randomly selected 4-6 mm periodontal pockets at baseline (T0) as well as 4 weeks (T1) and 12 weeks (T2) after NSPT. GCF levels of β-catenin, 8-OHdG, and TAC will be assayed by enzyme linked immunosorbent assay (ELISA).",[24,53],[79,80],"periodontitis","non surgical periodontal therapy","2026-05-18",{"date":83,"type":31},"2026-05-19",{"date":85,"type":20},"2026-07-15",{"date":87,"type":20},"2026-12-01",{"name":89,"class":38},"Zeyad Nazar",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":73,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":39},"100627036","microbiological-and-clinical-effects-of-pre--and-probiotics-in-non-surgical-periodontal-therapy-100627036","NCT07443410","Microbiological and Clinical Effects of Pre- and Probiotics in Non-Surgical Periodontal Therapy","PROPARO","Inclusion Criteria:\n\n* Age ≥ 18 years\n\n  * Stage III or IV periodontitis (localized or generalized)\n  * Ability to provide informed consent\n  * Written informed consent including data protection consent\n\nExclusion Criteria:\n\n* • Pregnancy or breastfeeding\n\n  * Conditions\u002Fmedications likely to substantially confound the oral microbiome or periodontal healing (e.g., uncontrolled diabetes mellitus, systemic immunosuppression, chronic steroid use)\n  * Antibiotic use within the last 3 months\n  * Use of oral pre-\u002Fprobiotic supplements within the last 3 months\n  * Recent subgingival instrumentation within the last 6 months\n  * Need for obligatory adjunctive systemic antibiotic prophylaxis\u002Ftherapy for NSPT\n  * Severe active systemic infection or other conditions judged by investigators to pose undue risk\n  * Regular use of antiseptic mouthrinses during the study period (unless medically required)\n  * Strict diets likely to substantially alter baseline microbiome trajectories (e.g., ketogenic, strict vegan) per protocol definition\n  * Chronic bowel diseases (for systemic confounding considerations)",{"count":98,"type":20},60,[75],"Periodontitis is a prevalent chronic inflammatory disease driven by a dysbiotic oral biofilm and a dysregulated host immune response. Standard non-surgical periodontal therapy (NSPT) is primarily mechanical and, in selected cases, may be accompanied by antiseptics or systemic antibiotics. Targeted modulation of the oral microbiome (\"microbiome engineering\") is currently not part of routine periodontal care due to limited high-quality evidence.\n\nPROPARO is a single-center, randomized, controlled pilot study designed to assess whether adjunctive oral supplementation with a probiotic containing Limosilactobacillus reuteri (commercial dietary supplement lozenge) alone or combined with vitamin B12 (commercial dietary supplement drops) is associated with changes in supragingival and subgingival oral microbiome composition during guideline-concordant NSPT compared with standard care alone. Participants with Stage III or IV periodontitis will be randomized 1:1:1 to: (1) NSPT\u002FSPT without supplementation (control), (2) NSPT\u002FSPT plus probiotic lozenges for 3 months, or (3) NSPT\u002FSPT plus probiotic lozenges and vitamin B12 drops for 3 months.\n\nThe primary outcome is change in oral microbiome composition and structure (supragingival and subgingival), assessed using 16S rDNA-based profiling and metagenomic sequencing approaches. Secondary outcomes include clinical periodontal parameters (e.g., probing depth, clinical attachment level, bleeding on probing), oral hygiene\u002Fgingival indices, dental status, and participant-level ecological covariates (diet quality, perceived stress, physical activity). Sampling and assessments are aligned with routine care time points from baseline through supportive periodontal therapy follow-up (up to 12 months). This pilot trial aims to generate feasibility and effect-size estimates to inform future confirmatory studies and potential translation into guideline-based periodontal care.",[24,102,103],"Periodontitis (Stage 3)","Periodontitis Stage IV",[25,105,106,107,108],"Non-surgical periodontal treatment","Probiotics","Prebiotics","Oral Microbiome","2026-02-24",{"date":111,"type":31},"2026-03-02",{"date":113,"type":31},"2024-10-25",{"date":115,"type":20},"2026-10",{"name":117,"class":38},"University Hospital Heidelberg",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":73,"phases":128,"briefSummary":130,"conditions":131,"keywords":138,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":39},"100615542","phase-2-3-month-clinical-trial-of-liquid-s-prf-in-periodontal-debridement-for-periodontitis-stages-ii-iv-100615542","NCT07293962","3-Month Clinical Trial of Liquid S-PRF in Periodontal Debridement for Periodontitis Stages II-IV","Liquid S-Platelet Rich Fibrin as a Potential Adjunct in Conservative Closed Periodontal Debridement for Periodontitis Stages II-IV: A Randomized, Split-mouth, 3-month Clinical Trial","Inclusion Criteria:\n\n* Have at least 20 teeth,\n* American Society of Anesthesiology class I or II\n* Periodontitis stages II-IV\n* Bilateral sites of deep periodontal pockets ≥5 mm\n\nExclusion Criteria:\n\n* Limited mouth opening or symptomatic temporomandibular joint disorder\n* Inability to tolerate extended long periodontal treatment and\u002For hyperactive gag reflex\n* Current or former smoker or vape user\n* Pregnant and\u002For breastfeeding\n* Having diabetes mellitus type I or II\n* Having bleeding disorder or is on anticoagulants\n* Underwent periodontal treatment and\u002For surgery in past 6 months prior\n* Undergoing orthodontic therapy, or completed in past 3 months prior\n* On or had anti-inflammatory drug(s) in past 3 months prior\n* On or had antibiotic(s) in past 3 months prior\n* Having autoimmune disorder\n* On or had immunosuppressant drug(s) in past 3 months prior\n* Undergoing or underwent radio- and\u002For chemo-therapy","65 Years",{"count":127,"type":20},14,[129],"PHASE2","What is the purpose of this study? This study is to investigate the effect of a processed blood product in healing after treatment for gum disease. In addition to scaling \\& root debridement (deep cleaning) that is the standard treatment for periodontitis, this study will test the effectiveness of patient's processed blood in improving healing of diseased gums.\n\nWhat are the procedures to be followed? First, all patients will undergo dental check-up and X-ray imaging for suitability as a participant for the project. For participants who are eligible and included into study, upper \\& lower jaws models will be made, and each will be given oral care kit \\& instructions. The next appointment will be given for scaling \\& root debridement with local numbing agent in one day. Towards the end of the treatment, a small amount (20 mℓ) of blood will be collected and spun to produce liquid platelet-rich fibrin that is then used to flush the treated gum pockets in half of the mouth. For the treated gum pockets in the opposite half of the mouth, sterile salt water (saline) will be used instead for comparison. Then, follow-up appointments are at monthly intervals until 3 months.\n\nWho should enter the study? Symptoms of gum disease include bleeding and\u002For receding gums, tooth\u002Fteeth appearing longer or feeling shaky\u002Floose\u002Fweak, formation of large amount of calculus and\u002For black\u002Fempty space between teeth, frequent\u002Frecurrent gum swelling\u002Fpus, and\u002For bad breath.",[132,133,102,25,134,135,136,24,137],"Periodontitis Stage II","Periodontitis Stage III","Periodontitis Chronic Localized Slight","Periodontitis Chronic Generalized Moderate","Periodontitis Chronic Generalized Severe","Periodontitis, Chronic",[139,79,140,141,142,143,144,145,146,147,148,149],"periodontal treatment","platelet concentrates","platelet-rich fibrin","nonsurgical","clinical trial","periodontal","nonsurgical periodontal debridement","dental scaling","periodontal diseases","periodontal debridement","nonsurgical periodontal treatment","2025-12-07",{"date":152,"type":31},"2025-12-19",{"date":154,"type":31},"2024-04-01",{"date":156,"type":20},"2026-03",{"name":158,"class":38},"Mahsa University",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":17,"enrollmentInfo":166,"targetDuration":4,"studyType":73,"phases":168,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":39},"100597090","the-effect-of-enamel-matrix-derivatives-on-gingival-tissue-thickness-100597090","NCT07053969","The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness","The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness. A Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Ability of subject to understand and the willingness to sign a written informed consent document.\n2. Males and females; Age 18 to 89 years old\n3. Require second stage implant uncovering\n4. In either the maxillary or mandibular arch\n5. Has consistent transportation for all clinical and study visits\n\nExclusion Criteria:\n\n1. Pregnancy, or those planning to become pregnant\n2. Allergy or any medical issue using EMD\n3. Non-English speaking\n4. Patients on anticoagulants\n5. Patients who object to the use of animal products",{"count":167,"type":20},32,[75],"Scientists do research to answer important questions which might help change or improve the way we do things in the future.\n\nThe investigators know that using Enamel Matrix Derivatives results in thicker gum tissues around teeth. This study will test to see if using EMD around implants results in thicker gum tissues around implants.",[171,172,24,173],"Dental Implantation","Missing Teeth","Mucositis",[175,176,177,178],"Enamel Matrix Derivatives","EMD","Keratinized mucosa width","Mucosal thickness","2025-11-10",{"date":181,"type":31},"2025-11-12",{"date":183,"type":31},"2025-08-31",{"date":185,"type":20},"2027-09",{"name":187,"class":38},"The University of Texas Health Science Center at San Antonio",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":73,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":39},"100587892","full-mouth-ultrasonic-debridement-carried-out-with-either-piezoelectric-or-magnetostrictive-device-100587892","NCT06934291","Full Mouth Ultrasonic Debridement Carried Out With Either Piezoelectric or Magnetostrictive Device","Clinical and Patient-Centered Outcomes of Full-Mouth Ultrasonic Debridement for Periodontitis: A Randomized Controlled Trial Comparing Piezoelectric and Magnetostrictive Devices","Inclusion Criteria:\n\n* \\>18 years\n* periodontitis of stage 1 and 2\n* absence of systemic chronic disease\n\nExclusion Criteria:\n\n* anticoagulants treatment\n* antibiotic treatment 3 months before the screening visit","80 Years",{"count":197,"type":20},52,[75],"The treatment of periodontitis requires the removal of dental biofilm through both professional mechanical plaque removal and at-home oral hygiene practices. This study aims to compare clinical and psychological outcomes following professional treatment using either piezoelectric or magnetostrictive ultrasonic devices.",[24],[79,202,203],"patient centred outcomes","magnetostrictive","2025-09-03",{"date":206,"type":31},"2025-09-10",{"date":208,"type":31},"2025-03-31",{"date":210,"type":20},"2025-10",{"name":212,"class":38},"University of Siena",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":73,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":39},"100568710","a-chitosan-brush-and-enamel-matrix-derivative-for-non-surgical-treatment-of-furcations-100568710","NCT06684769","A Chitosan Brush and Enamel Matrix Derivative for Non-surgical Treatment of Furcations","Non-surgical Treatment of Mandibular and Maxillary Molar Furcations With a Chitosan Brush With Adjunct Enamel Matrix Derivative- a Split-mouth Randomized Clinical Trial","Inclusion criteria:\n\n1. The patient is 18 years of age or older\n2. The patient does not have any systemic diseases that may affect the results of the study\n3. The patient has a plaque index of 20% or less at the study entry\n4. The patient has a history of severe localized or generalized periodontitis (stage III or IV)\n5. Completed the first and second steps of periodontal treatment (According to Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline) (Sanz M. et al.)\n6. Buccal and\u002For lingual Class 2A and\u002For 2B furcation involvement (FI) defects on both sides of the Mandibular first and\u002For second molars after completing the first and second steps of periodontal treatment.\n7. Buccal Class 2A and\u002For 2B furcation involvement (FI) defects on both sides of the maxillary first and\u002For second molars after completion of the first and second step of periodontal treatment if furcation involvement on the palatal side (mesiopalatal and distopalatal) does not exceed Class 1.\n8. Psychological appropriateness\n9. Consents to all follow-up visits\n\nExclusion Criteria:\n\n1. Patients who have systemic diseases that may affect the results of the study\n2. Use of medications that may affect study results (anti-osteoporotic drugs, statins, corticosteroids, anticoagulants)\n3. Patients who use calcium channel blockers, cyclosporine A or antiepileptic drugs if there are clinically visible hyperplastic changes in the gingival margin.\n4. Patients who have received any type of systemic antibiotics in the last six months prior to the start of the study and patients starting antibiotics during the study\n5. Patients requiring antibiotic premedication prior to periodontal treatment\n6. Oncological disease\n7. Chemotherapy and\u002For radiotherapy (active or history)\n8. Pregnancy and breastfeeding\n9. Any condition or current treatment which, in the opinion of the investigator and\u002For consulting physician, may present an unreasonable risk\n10. Psychoemotional disorders and depression\n11. Use of antipsychotic medication or antidepressants\n12. Lack of patient motivation to undertake adequate dental care at home or complete periodontal treatment, patients residing outside Latvia\n13. Molars with combined endodontic-periodontal lesions, active endodontic infection\n14. Prosthetic factors for molars not allowing clinical measurements\n15. Huge restoration or amalgam fillings that could potentially cause fractures or furcation involvement\n16. Enamel pearls or filling or crown margins\n17. Decay or root resorption\n18. Tooth mobility degree 3\n19. Molars in which the gingival margin is positioned apically from the entrance into the furcation area\n20. Clinical attachment level and or pockets mesial and distal to the furcation involvement defect of 6 or more mm\n21. Strong vomiting reflex that would prevent adequate periodontal treatment\n22. People close to the study subjects, work colleagues, relatives, etc.",{"count":221,"type":20},40,[75],"Patients diagnosed with stage III or IV periodontitis who exhibit mandibular first or second molars with Class II, Subclass A, or B buccal and\u002For lingual mandibular furcation defects (horizontal probing depth of ≥ 3 mm ) will be recruited.\n\nPatients diagnosed with stage III or IV periodontitis who exhibit maxillary first or second molars with Class II, Subclass A, or B buccal furcation defects (horizontal probing depth of ≥ 3 mm ) if furcation involvement on the palatal side (mesiopalatal and distopalatal) does not exceed Class 1 will be recruited.\n\nThis study will be a prospective, randomized, single-blinded, controlled clinical trial with a split-mouth design.\n\nPatients will be recruited from the clinics of the Riga Stradiņš University Institute of Stomatology of Riga, Latvia.\n\nBefore the baseline treatment, all patients who meet the inclusion criteria will be given detailed oral hygiene instructions and motivation.\n\nPatients' furcation defects in each quadrant will be randomly allocated at a 1:1 ratio to either the application of Oscillating Chitosan Brush with Enamel Matrix Derivatives (test group) or Oscillating Chitosan Brush alone (control group).\n\nNon-surgical periodontal treatment of furcation defects on the test side will be performed through the application of Oscillating Chitosan Brush with Enamel Matrix Derivatives and on the control side with Oscillating Chitosan Brush alone.\n\nThe re-evaluation of periodontal status will be performed 12 weeks following the baseline treatment.\n\nBiofilm samples and gingival crevicular fluid (GCF) samples will be taken at the baseline and at 4 weeks.",[24,225,226,227],"Furcation Defects","Furcation of Root of Tooth","Periodontitis Complex",{"date":229,"type":31},"2025-09-08",{"date":231,"type":31},"2024-11-15",{"date":233,"type":20},"2026-11",{"name":235,"class":38},"Riga Stradins University",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":125,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100556701","impact-of-smoking-on-salivary-interleukin-il-39-il-41-il-1-tnf--levels-in-periodontal-disease-100556701","NCT06528522","Impact of Smoking on Salivary Interleukin (IL)-39, IL-41, IL-1β, TNF-α Levels in Periodontal Disease","Impact of Smoking on Salivary Inflammatory Cytokines (Interleukin (IL)-39, IL-41, IL-1β, TNF-α) in Periodontal Disease","Inclusion Criteria:\n\n* The periodontitis groups (Non-smoking and smoking) in the study will include systemically healthy patients who are clinically diagnosed with Stage II and III, generalized, Grade B, C periodontitis based on the consensus report of the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions.\n* Agreeing to participate in the study\n\nExclusion Criteria:\n\n* use of oral contraceptive drugs\n* use of antibiotics, immunosuppressants, or drug therapies in the last 6 months before the study;\n* history of excessive alcohol use;\n* pregnancy or breastfeeding status;\n* periodontal treatment during the last 6 months before the study.\n* Not agreeing to participate in the study\n* Not meeting the inclusion criteria",{"count":19,"type":20},"The goal of this observational study is to evaluate if the measurement of salivary Interleukin (IL)-39, IL-41, IL-1Beta(β), and Tumor necrosis factor-alpha (TNF-α) levels can aid in the early diagnosis of periodontitis in patients with varying periodontal conditions, both smokers and non-smokers. The main questions it aims to answer are:\n\nCan salivary IL-39, IL-41, IL-1β, and TNF-α levels be used as biomarkers for the early diagnosis of periodontitis? How do IL-41 and IL-39 levels correlate with smoking status in periodontal healthy and periodontitis patients? Researchers will compare the salivary biomarker levels between smokers and non-smokers to see if smoking affects these levels.\n\nParticipants will:\n\nProvide salivary samples for biomarker analysis. Undergo a comprehensive periodontal examination to determine their periodontal status.",[24,246,53],"Smoking",[79,248,249],"cytokines","saliva","2024-07-25",{"date":252,"type":31},"2024-07-30",{"date":254,"type":20},"2024-08-01",{"date":256,"type":20},"2024-09-15",{"name":258,"class":38},"Necmettin Erbakan University"]